Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 2 institutions in 1 country.
Motoyasu MiyazakiDepartment of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan.ORCID 0000-0002-4526-3045
Ryoko YanagidaDepartment of Pharmacy, Fukuoka University Chikushi Hospital, Chikushino 818-8502, Japan.
Akio NakashimaDepartment of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan.
Koichi MatsuoDepartment of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan.
Norihiro MoriwakiDepartment of Pharmacy, Fukuoka University Hospital, Fukuoka 814-0180, Japan.
Masanobu UchiyamaDepartment of Pharmacy, Fukuoka University Chikushi Hospital, Chikushino 818-8502, Japan.
Yota YamadaDepartment of Pharmacy, Fukuoka University Chikushi Hospital, Chikushino 818-8502, Japan.
Hitomi HirataDepartment of Pharmacy, Fukuoka University Chikushi Hospital, Chikushino 818-8502, Japan.
Hisako KushimaDepartment of Respiratory Medicine, Fukuoka University Chikushi Hospital, Chikushino 818-8502, Japan.
Yoshiaki KinoshitaDepartment of Respiratory Medicine, Fukuoka University Chikushi Hospital, Chikushino 818-8502, Japan.ORCID 0000-0002-8872-8957
Hiroshi IshiiDepartment of Respiratory Medicine, Fukuoka University Chikushi Hospital, Chikushino 818-8502, Japan.ORCID 0000-0002-2143-5922
Osamu ImakyureDepartment of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan.
Fukuoka University · JPFukuoka University Hospital · JP
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19 Drug TreatmentAdenosine MonophosphateAlanineHumansOxygenRetrospective StudiesSARS-CoV-2Adenosine MonophosphateAlanineOxygenremdesivircoronavirusCOVID-19oxygen therapyremdesivir
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study. · full record | OpenQuestion